Dr. Matt Coffey reports

ONCOLYTICS BIOTECH ANNOUNCES A MASTER CLINICAL SUPPLY AGREEMENT OF AN ANTI-PD-L1 CHECKPOINT INHIBITOR FOR USE IN THE COMPANY'S CLINICAL PROGRAM

Oncolytics Biotech Inc. has entered into a master clinical supply agreement with F. Hoffmann-La Roche Ltd. to supply atezolizumab (Tecentriq) for use in the company's clinical development program.

"The supply agreement enables us to further investigate pelareorep's impact on cancer treatments in combination with atezolizumab," said Dr. Matt Coffey, president and chief executive officer of Oncolytics Biotech. "We plan on incorporating this anti-PD-L1 cancer immunotherapy into our clinical program immediately. Data from these studies will broaden our experience with this drug class as we look to demonstrate the impact of pelareorep with checkpoint inhibitors."

Under this five-year master clinical supply agreement, Roche will supply atezolizumab for the proposed clinical trial with both parties having access to the clinical data.

About pelareorep

Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus being evaluated for the treatment of solid tumours and hematological malignancies. The compound induces selective tumour lysis and promotes an inflamed tumour phenotype through innate and adaptive immune responses to treat a variety of cancers.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumour lysis and promotes an inflamed tumour phenotype -- turning cold tumours hot -- through innate and adaptive immune responses to treat a variety of cancers. Oncolytics's clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumour lysis, and immunotherapy and immune modulator (IMiD) combinations to produce innate and adaptive immune responses. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted and IMiD therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer.

We seek Safe Harbor.